Condition: Dystonia · Sponsor: Vima Therapeutics
Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve dystonia symptoms compared to placebo? * Is VIM0423 well tolerated in individuals with isolated dystonia? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
This description comes directly from the study's public registry record.
Study Director · 617-430-7027 · Clinicaltrials@vimatx.com
Always discuss trial participation with your own doctor first.
| Vima Site #033 | Birmingham, Alabama, United States | Not Yet Recruiting |
| Vima Site #039 | Scottsdale, Arizona, United States | Not Yet Recruiting |
| Vima Site #004 | Scottsdale, Arizona, United States | Recruiting |
| Vima Site #028 | Sun City, Arizona, United States | Not Yet Recruiting |
| Vima Site #042 | Irvine, California, United States | Recruiting |
| Vima Site #030 | Los Angeles, California, United States | Not Yet Recruiting |
| Vima Site #019 | Denver, Colorado, United States | Recruiting |
| Vima Site #009 | Gainesville, Florida, United States | Recruiting |
| Vima Site #008 | Miami, Florida, United States | Recruiting |
| Vima Site #031 | Orlando, Florida, United States | Recruiting |
| Vima Site #005 | Atlanta, Georgia, United States | Not Yet Recruiting |
| Vima Site #027 | Chicago, Illinois, United States | Not Yet Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07304089